Exact Sciences/EXAS

1.71%
-
1D1W1MYTD1YMAX

About Exact Sciences

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Ticker

EXAS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Conroy

Employees

6,500

Headquarters

Madison, United States

Exact Sciences Metrics

BasicAdvanced
US$9.3B
Market cap
-
P/E ratio
-US$1.32
EPS
1.27
Beta
-
Dividend rate
US$9.3B
1.27362
US$100.77
US$50.35
2.8M
1.635
1.448
66.395
76.138
-3.79%
-7.76%
-4.13%
3.668
2.957
15.21%
54.58%
18.79%

What the Analysts think about Exact Sciences

Analyst Ratings

Majority rating from 23 analysts.
Buy

Price Targets

Average projection from 20 analysts.
69.22% upside
High US$100.00
Low US$66.00
US$51.24
Current price
US$86.71
Average price target

Exact Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-17.28% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$638M
-1.44%
Net income
-US$110M
121.73%
Profit margin
-17.28%
125%

Exact Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 27.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.45
-
-US$0.27
-US$0.60
-
Expected
-US$0.51
-US$0.48
-US$0.46
-US$0.47
-US$0.30
Surprise
-11.68%
-
-41.21%
27.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Exact Sciences stock?

Exact Sciences (EXAS) has a market cap of $9.3B as of May 20, 2024.

What is the P/E ratio for Exact Sciences stock?

The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of May 20, 2024.

Does Exact Sciences stock pay dividends?

No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Exact Sciences dividend payment date?

Exact Sciences (EXAS) stock does not pay dividends to its shareholders.

What is the beta indicator for Exact Sciences?

Exact Sciences (EXAS) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Exact Sciences stock price target?

The target price for Exact Sciences (EXAS) stock is $86.71, which is 70.02% above the current price of $51. This is an average based on projections from 20 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Exact Sciences stock

Buy or sell Exact Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing